Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)
Hong Kong · Delayed Price · Currency is HKD 6.30
+0.05 (0.80%)
Jul 10, 2026, 11:31 AM HKT
HKG:2566 Revenue
In the year 2025, Hangzhou Jiuyuan Genetic Biopharmaceutical had annual revenue of 1.31B CNY, down -4.59%. Hangzhou Jiuyuan Genetic Biopharmaceutical had revenue of 667.52M in the half year ending December 31, 2025, with 6.98% growth.
Revenue
1.31B CNY
Revenue Growth
-4.59%
P/S Ratio
1.04
Revenue / Employee
728.15K CNY
Employees
1,794
Market Cap
1.51B HKD
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31B | -62.88M | -4.59% |
| Dec 31, 2024 | 1.37B | 81.78M | 6.35% |
| Dec 31, 2023 | 1.29B | 162.00M | 14.40% |
| Dec 31, 2022 | 1.13B | -181.85M | -13.91% |
| Dec 31, 2021 | 1.31B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 2.00B |
| AIM Vaccine | 1.30B |
| Mabpharm | 718.98M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 171.70M |
| CANbridge Pharmaceuticals | 55.62M |
| Beijing Biostar Pharmaceuticals | 37.13M |
| Zhaoke Ophthalmology | 35.58M |
| SinoMab BioScience | 6.28M |